




Community oncology.  
 v. 6, no. 3 (Mar. 2009)  
 General Collection  
 W1 CO429TN  
 2009-04-18 12:28:46



# COMMUNITY ONCOLOGY

THE ISSUES THAT MATTER TO YOU, YOUR PRACTICE, AND YOUR PATIENTS

REVIEW ARTICLE

Identifying and treating **imatinib failure in CML:**  
 a review of treatment guidelines and available agents  
 Stuart L. Goldberg and Aisha Masood

WASHINGTON UPDATE

Can we fix the **economy and healthcare?**  
 A report from the 4<sup>th</sup> Annual Community Oncology Conference  
 Caroline Helwick

PHARMACOGENETICS

**Personalized therapy**  
 A new era for cancer treatment?  
 Jeffrey Allen and Clinton F. Stewart

ADVERSE EVENTS ALERT

Anaphylaxis caused by **Cremophor EL-containing paclitaxel:** preventing and treating a hypersensitivity reaction  
 Lauren D. Irizarry et al

BRIEF COMMUNICATIONS

Elevated alpha-fetoprotein levels and **liver lesions** in the absence of hepa

Nazik

```

#BXNLRZG ****CAR-RT LOT**C-006
PD SUB
SWETS INFORMATION SERVICES INC.
160 NINTH AVE, STE A
  
```

```

P0026
13162
32066
V9002
  
```

Volum **RUNNEMEDE NJ 08078-1161**  
 March 2009

ite table of contents  
 jes 94 and 96

Community Oncology is  
published by



ONCOLOGY

Elsevier Oncology  
46 Green Street, 2nd Floor  
Huntington, NY 11743  
631.424.8900 tel • 631.424.8905 fax

Randi Londer Gould, *Managing Editor*  
Gail M. van Koot, *Editorial Manager*  
Susan Reckling, MA, *Copy Editor*  
Caroline Helwick, *Contributing Writer*  
Edwin S. Geffner, *Design Director*  
Wendy McGullam, *Production Manager*  
Devin Gregorie, *National Accounts Manager*  
Kelly McNulty, *National Sales Manager*  
Dan H. Kim, *President and Publisher*

*Community Oncology* (ISSN 1548-5315) is published monthly by Elsevier Inc., Elsevier Oncology, 46 Green Street, 2nd Floor, Huntington, NY 11743. Periodicals postage paid at Huntington, NY, and additional mailing offices.

#### Change of Address

Postmaster: send address changes to *Community Oncology*, Circulation, Elsevier Inc., 60B Columbia Road, Morristown, NJ 07960. Recipient: to change your address, contact b.cavallaro@elsevier.com or mail to *Community Oncology*, Circulation, Elsevier Inc., 60B Columbia Road, Morristown, NJ 07960.

**On the cover** Colored scanning electron micrograph of blood cells in a patient suffering from leukemia. Four white blood cells (leukocytes, brown/green) and two red blood cells (erythrocytes, red) are seen. Photo: Steve Gschmeissner/Photo Researchers, Inc.

#### Editor-in-Chief

Lee S. Schwartzberg, MD, FACP  
The West Clinic

#### Editors

Linda D. Bosserman, MD, FACP  
Wilshire Oncology Medical Group

David H. Henry, MD, FACP  
Pennsylvania Hospital

#### Editorial Board

Carolyn R. Aldigé  
Cancer Research and Prevention Foundation

Paul N. Anderson, MD  
Rocky Mountain Cancer Center

Francis P. Arena, MD  
Arena Oncology Associates

Ralph V. Boccia, MD  
Georgetown University

Susan Carter, PhD  
Claremont, CA

Barrie R. Cassileth, PhD  
Memorial Sloan-Kettering Cancer Center

Lawrence R. Coia, MD  
Community-Kimball Regional Cancer Center

Steven M. Coplton, MHA  
The West Clinic

Barry Fortner, PhD  
P4 Healthcare

John A. Fracchia, MD  
Lenox Hill Hospital

James N. George, MD  
University of Oklahoma Health Sciences Center

Michael S. Gordon, MD  
Premiere Oncology of Arizona

Richard J. Gralla, MD  
Multinational Association for Supportive Cancer Care

Patrick Grusenmeyer, ScD  
Helen F. Graham Cancer Center

Mary Helen Hackney, MD  
Massey Cancer Center

I. Craig Henderson, MD  
University of California, San Francisco

David M.J. Hoffman, MD  
Tower Hematology Oncology Medical Group

Dawn G. Holcombe, FACMPE  
DGH Consulting and  
Connecticut Oncology Association

Jimmie Holland, MD  
Memorial Sloan-Kettering Cancer Center

Frankie Ann Holmes, MD  
US Oncology, Houston

L. Wayne Keiser, MD  
Redwood Regional Medical Group

Mary Kruczynski  
Community Oncology Alliance

#### Section Editors

COMMUNITY TRANSLATIONS  
Jame Abraham, MD  
West Virginia University

ADVERSE EVENTS ALERT  
Charles L. Bennett, MD, PhD, MPP  
Feinberg School of Medicine  
Northwestern University

CASES IN COMMUNITY ONCOLOGY  
Michael A. Danso, MD  
US Oncology, Cancer Centers of Florida

Leslie Rodgers Laufman, MD  
Hematology Oncology Consultants

Stuart M. Lichtman, MD  
Memorial Sloan-Kettering Cancer Center  
at Suffolk

John S. Macdonald, MD  
St. Vincent's Comprehensive Cancer Center

John L. Marshall, MD  
Lombardi Comprehensive Cancer Center

Cathy Maxwell, RN, OCN, CCRC  
Advanced Medical Specialties, LLC

Bradley J. Monk, MD, FACOG  
Chao Family Comprehensive Cancer Center

Anne Moore, MD  
Weill Medical College of Cornell University

Timothy D. Moore, MD  
Mid Ohio Oncology/Hematology

Deborah A. Nagle, MD  
Beth Israel Deaconess Medical Center

Ricky Newton, CPA  
Cancer Specialists of Tidewater

Theodore A. Okon, MBA  
Supportive Oncology Services

Edith A. Perez, MD  
Mayo Clinic, Jacksonville

Philip A. Philip, MD, PhD  
Barbara Ann Karmanos Cancer Institute

Nicholas J. Robert, MD  
US Oncology, Fairfax

Peter J. Rosen, MD  
Tower Cancer Research Foundation

Myrna R. Rosenfeld, MD, PhD  
University of Pennsylvania School of Medicine

Mark Santos, RPh  
International Oncology Network

Philip Schulman, MD  
Memorial Sloan-Kettering Cancer Center  
at Suffolk

Jeffrey A. Scott, MD  
P4 Healthcare

N. Simon Tchekmedyan, MD  
Pacific Shores Medical Group

Steven Tucker, MD  
West Clinic Excellence Cancer Center

James L. Wade III, MD  
Decatur Memorial Hospital  
Cancer Care Institute

## Guide for Authors

*Community Oncology* serves as a forum and resource for more than 31,000 practice-based oncologists, hematologists, oncology nurses, pharmacists, and administrators.

### TYPES OF ARTICLES

**Brief Communications** Short case reports.  
**Challenging Cases/Rare Cancers** Expert opinion and resources.

**Community Translations** places pivotal new research findings into the context of community practice.

**Controversies in Patient Management** looks at the difficult questions that arise when delivering quality care.

**Economics/Practice Management** How to make your practice more efficient.

**Having Your Say** Guest editorials.

**Managing Side Effects** Clinical articles on dealing with comorbidities.

**Nurse Management** Nursing perspective on patient care and managing side effects.

**Original Contributions** Peer-reviewed articles ranging from retrospective reviews to original observations and results of clinical trials conducted in the community setting.

**Practice Survival** Personal essays.

**Psychosocial Oncology** details the spiritual, psychological, social, and emotional side of cancer care.

**Quality Care** Issues ranging from pay-for-performance to implementing treatment guidelines in your practice.

### MANUSCRIPT SUBMISSION

**Manuscripts** should be sent to the journal as an e-mail attachment, addressed to Gail van Koot, Editorial Manager, [g.vankoot@elsevier.com](mailto:g.vankoot@elsevier.com). Original contributions are subject to peer review in the usual manner. Generally, articles will be published within 8 weeks of acceptance.

**The Editors require that authors disclose all potential conflicts of interest.**

*Community Oncology* conforms, in general, to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (*N Engl J Med* 1997;336:309-315). For additional information, please visit our Web site at [www.communityoncology.net](http://www.communityoncology.net).

### LETTER FROM THE EDITOR

## 99 Cancer treatment: it's getting personal

Lee S. Schwartzberg, MD, FACP, *The West Clinic, Memphis, TN*

This issue of *Community Oncology* focuses on a number of aspects of personalized medicine. At this moment, the grand vision of tailoring therapy to a tumor-specific target while calibrating dosages according to underlying subtle metabolic differences in each patient remains more a theory than a reality. Yet there has been remarkable progress already, with practical implications for clinicians.

### LETTER TO THE EDITOR

## 105 5-Fluorouracil-induced cardiotoxicity: hints for predicting patients at risk

Jan Cerny, MD, and Bilal Piperdi, MD, *Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, MA*

**Dr. Tejwani responds**

Sheela Tejwani, MD, FACP, *Senior Staff Physician, Division of Hematology/Oncology, Josephine Ford Cancer Center, Henry Ford Hospital, Detroit, MI*

### BRIEF COMMUNICATIONS

## 108 Two patients with elevated alpha-fetoprotein levels and liver lesions in the absence of hepatocellular carcinoma

Nazik Hammad, MD, MSc, Philip A. Philip, MD, PhD, and Bassel F. El-Rayes, MD, Hind Nassar, MD, and Kaleford Hong, MD, *Division of Hematology and Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI; Department of Pathology, Johns Hopkins University, Baltimore, MD; Department of Radiology, Wayne State University, Detroit, MI*

Two cases demonstrate the limitations of using alpha-fetoprotein levels to diagnose hepatocellular carcinoma in patients with hepatitis virus C infection.

### REVIEW ARTICLE

## 113 Identifying and treating imatinib failure in chronic myelogenous leukemia: a practical review of treatment guidelines and available agents

Stuart L. Goldberg, MD, and Aisha Masood, MD, *Division of Leukemia, The John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ*

Although most patients respond to imatinib and achieve prolonged remission, the development of imatinib resistance has emerged as a major clinical issue. Two recently approved tyrosine kinase inhibitors, the dual BCR-ABL and SRC inhibitor dasatinib and the imatinib analogue nilotinib, have shown substantial activity among patients with resistance or intolerance to imatinib. Given these new options, identification of nonresponders has become increasingly important to ensure the earliest administration of appropriate therapy. The authors review recommendations for identifying and treating patients with chronic-phase chronic myelogenous leukemia who have experienced failure of first-line imatinib.

# COMMUNITY ONCOLOGY

## Correspondence

Inquiries should be addressed to *Community Oncology*, 46 Green Street, 2<sup>nd</sup> Floor, Huntington, NY 11743; tel: 631-424-8900; fax: 631-424-8905.

Editorial correspondence, including submissions for publication or Letters to the Editor, should be addressed to the Editor-in-Chief, Lee S. Schwartzberg, MD, FACP, e-mail: editor@communityoncology.net.

Authors' guidelines may be found online at [www.communityoncology.net/guide.html](http://www.communityoncology.net/guide.html). For additional information, contact the Editorial Office, 631-424-8900, or e-mail the Editorial Manager, Gail van Koot, [g.vankoot@elsevier.com](mailto:g.vankoot@elsevier.com).

## Advertising

For information on advertising rates, reprints, or supplements, contact Devin Gregorie, tel: 631-424-8900 ext 305, e-mail: [d.gregorie@elsevier.com](mailto:d.gregorie@elsevier.com).

## Copyright

Copyright © 2009 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher.

## Subscriptions

Annual subscription rates (12 issues): *Individual*: US \$257; Canada: US \$269; International: US \$297. *Institutional*: US \$328; Canada: US \$355; International: US \$362. *Single copy*: US \$40. For further information regarding subscriptions, contact [subscriptions@communityoncology.net](mailto:subscriptions@communityoncology.net).

*Community Oncology* (ISSN 1548-5315) is published monthly by Elsevier Oncology, 46 Green Street, 2<sup>nd</sup> Floor, Huntington, NY 11743.

## Disclaimer

Discussions, views, opinions, and recommendations as to medical procedures, products, choice of drugs, and drug dosages are the responsibility of the authors or advertisers. No responsibility is assumed by the Publisher, Editor, or Editorial Board for any injury and/or damage to persons or property as a matter of product liability, negligence, or otherwise or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made. Advertiser and advertising agency recognize, accept, and assume liability for all content (including text, representations, illustrations, opinions, and facts) of advertisements printed and also assume responsibility for any claims made against the Publisher arising from or related to such advertisements.

In the event that legal action or a claim is made against the Publisher arising from or related to such advertisements, advertiser and advertising agency agree to fully defend, indemnify, and hold harmless the Publisher and to pay any judgment, expenses, and legal fees incurred by the Publisher as a result of said legal action or claim. The Publisher reserves the right to reject any advertising that he feels is not in keeping with the publication's standards.

The Publisher is not liable for delays in delivery and/or non-delivery in the event of Act of God, action by any government or quasi-governmental entity, fire, flood, insurrection, riot, explosion, embargo, strikes (whether legal or illegal), labor or material shortage, transportation interruption of any kind, work slowdown, or any condition beyond the control of the Publisher that affects production or delivery in any manner.

This journal is printed on paper meeting the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper) effective with Volume 1, Issue 1, 2004.



## PHARMACOGENETICS

### 126 Personalized therapy for cancer: has pharmacogenetics delivered?

Jeffrey Allen, MD, and Clinton F. Stewart, PharmD, *University of Tennessee Cancer Institute, Memphis, TN, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN*

The prescribing information for several drugs has already been changed on the basis of pharmacogenetic data. In addition, two drugs—irinotecan, a camptothecin analog with activity in a number of solid tumors, and tamoxifen, a selective estrogen receptor modulator with activity in breast and uterine cancers—have been the focus of intense pharmacogenetic investigations over the past decade. For patients and oncologists alike, pharmacogenetic studies on these drugs and others are opening the door to a new era of personalized anticancer therapy.

## ADVERSE EVENTS ALERT

### 132 Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action

Lauren D. Irizarry, BA, Thanh Ha Luu, BA, June M. McKoy, MD, JD, MPH, Athena T. Samaras, BA, Matthew J. Fisher, BA, Edson E. Carias, BA, Dennis W. Raisch, PhD, RPh, Elizabeth A. Calhoun, PhD, and Charles L. Bennett, MD, PhD, *MPP, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL; VA Midwest Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL; Division of Geriatric Medicine, Northwestern University, Feinberg School of Medicine; The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; University of New Mexico College of Pharmacy and VA Cooperative Studies Program, Albuquerque, NM; University of Illinois, Chicago, IL*

Published literature indicates that hypersensitivity reactions to cremophor-containing paclitaxel occur quite often and are of varied severity. The authors review the problem and make a number of recommendations for prevention and treatment.

## WASHINGTON UPDATE

### 135 The tallest order: fixing the economy and healthcare

Caroline Helwick

The current fiscal crisis is taking center stage, and although healthcare is a key part of our financial woes, fixing the economy will have to come first—at least for now. A report on the legislative roundtable at the 4<sup>th</sup> Annual Community Oncology Conference.

Community Oncology is indexed by EMBASE and the Cumulative Index to Nursing and Allied Health Literature (CINAHL)

# Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action

Lauren D. Irizarry, BA,<sup>1,2</sup> Thanh Ha Luu, BA,<sup>1,2</sup> June M. McKoy, MD, JD, MPH,<sup>3,4</sup> Athena T. Samaras, BA,<sup>1,2</sup> Matthew J. Fisher, BA,<sup>1,2</sup> Edson E. Carias, BA,<sup>1,2</sup> Dennis W. Raisch, PhD, RPh,<sup>5</sup> Elizabeth A Calhoun, PhD,<sup>6</sup> and Charles L. Bennett, MD, PhD, MPP<sup>1,2,4</sup>

<sup>1</sup>Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL;

<sup>2</sup>VA Midwest Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL;

<sup>3</sup>Division of Geriatric Medicine, Northwestern University, Feinberg School of Medicine; <sup>4</sup>The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; <sup>5</sup>University of New Mexico College of Pharmacy and VA Cooperative Studies Program, Albuquerque, NM; <sup>6</sup>University of Illinois, Chicago, IL

**H**ypersensitivity reactions to Cremophor EL-containing paclitaxel range from mild pruritus to systemic anaphylaxis and can result in potentially severe clinical outcomes, including respiratory arrest, cardiac collapse, and death.<sup>1</sup>

## Fast Facts

ANAPHYLAXIS and severe hypersensitivity reactions are known to occur in patients during paclitaxel infusion. In early phase I studies of paclitaxel, there were a number of anaphylactic reactions and deaths, which raised great concern about the potential development of this drug.<sup>2</sup> Although the exact mechanism of these reactions to Cremophor-containing paclitaxel is not known, these responses are clinically consistent with a type I hypersensitivity reaction, an immediate, immunoglobulin E-mediated reaction. The hypersensitivity reactions may result from direct mast cell degranulation induced by either the chemotherapeutic agent itself or by Cremophor EL.<sup>1,3</sup>

It is generally believed that such reactions are due to the surfactant Cremophor EL, because these effects have also been observed in other drugs utilizing it. The amount of Cremophor EL used in paclitaxel is considerably larger than the amount used in other marketed products and anaphylaxis can occur despite the use of premedication.<sup>2,4</sup>

In Cremophor EL-containing paclitaxel clinical trials, up to 41% of patients experienced a hypersensitivity reaction. From 2%–4% of patients experienced anaphylaxis or a severe hypersensitivity reaction, characterized by dyspnea, hypotension, angioedema, and generalized urticaria.<sup>5</sup> Hypersensitivity reactions occurred even in patients who received prophylaxis.<sup>6</sup>

Up to 95% of hypersensitivity reactions to taxanes occurred during administration of the first or second dose, and almost 80% of symptoms developed during the first 10 minutes of infusion, with many reactions occurring after only 1 mg was infused.<sup>1</sup> A black-box warning on the drug's package insert alerts patients and healthcare professionals to the potential occurrence of fatal hypersensitivity reactions. Although hypersensitivity reaction prophylaxis is recommended, neither the frequency of use nor the efficacy of premedication prophylactic measures is known.

## Pharmacovigilance

As with all serious and potentially fatal adverse drug reactions, the US Food and Drug Administration (FDA) MedWatch database represents an important source of safety

information. This is particularly relevant for Cremophor EL-containing paclitaxel-associated hypersensitivity, where the potential for severe anaphylaxis or death exists. No prior study has investigated FDA MedWatch reports for Cremophor EL-containing paclitaxel-associated hypersensitivity.

Investigators affiliated with the Research on Adverse Drug Events and Reports (RADAR), an established pharmacovigilance program, reviewed case reports of paclitaxel-induced hypersensitivity reactions from the FDA's Adverse Event Report System.<sup>7</sup> Our objectives were to 1) assess the quality and timing of individual case reports of serious or fatal paclitaxel hypersensitivity reactions submitted to regulatory agencies in the United States, Europe, and Japan; and 2) evaluate whether any of these events occurred despite the use of premedication prophylaxis (Table 1).

## What we reported

In a review of adverse event reports submitted to regulatory agencies between 1997 and 2007 in the United States, Europe, and Japan, 171 unique cases of Cremophor EL-containing paclitaxel-associated hypersensitivity

*Dr. Raisch has an unrestricted grant from Abraxis.*

© 2009 Elsevier Inc. All rights reserved.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.